Clinical Trial Update: Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating an SGLT2 inhibitor for cognitive function in adults with type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Type 2 Diabetes Mellitus

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: Third Military Medical University | Conditions: Diabetes Mellitus, Type 2, Cognitive Functions Confusion | Phase 3 | Status: COMPLETED